ArticleArchives of pharmacal research2023

Selumetinib overcomes gefitinib primary and acquired resistance by regulating MIG6/STAT3 in NSCLC.

Xiaoping Song et al.PubMed ↗Publisher ↗

No numbers read from the abstract.